The generic drug supply chain sprawls across the globe and is pretty opaque. Manufacturers are required to report to the FDA when there’s a disruption that could impact supply, but the details aren’t always shared with the public and can be protected as proprietary information
Only about 30% of API manufacturing facilities that supply ingredients for drugs for the US market are themselves based in the US. The rest are spread across places like India, China, and the EU